SARVARI YELLAPRAGADA to Bortezomib
This is a "connection" page, showing publications SARVARI YELLAPRAGADA has written about Bortezomib.
Connection Strength
0.085
-
More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected]. Blood Adv. 2023 10 24; 7(20):6275-6284.
Score: 0.055
-
A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. Br J Haematol. 2015 Apr; 169(1):36-43.
Score: 0.030